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To demonstrate the validity of sentinel lymph node biopsy (SLNB) using the indocyanine 
green dye method (dye only method), we compared the survival of breast cancer patients 
negative to SLNB without axillary lymph node dissection (ALND) (SLNB group) to that of 
lymph node-negative patients undergoing ALND (ALND group).  We studied a total of 174 
patients with T1-2N0 invasive breast cancer diagnosed at our university hospital clinical 
department between 2000 and 2008, with follow-up till 31 December 2009, retrospectively. 
The SLNB group consisted of 108 SLNB-negative women without additional ALND (median 
follow-up, 25 months), diagnosed between May 2005 and 2008.  The ALND group consist-
ed of 66 axillary lymph node-negative women (median follow-up, 75 months) treated with 
ALND between 2000 and April 2005.  SLNB was performed during operation by peri-
areolar injection using indocyanine green.  All sentinel lymph nodes were examined using 
the largest section along the major axis, and permanent sections were stained with hema-
toxylin and eosin.  In the SLNB group, no patients developed axillary recurrence during 
the 25-month median follow-up.  The 4.5-year distant disease free survival and overall sur-
vival rates were 90.9% and 91.9%, respectively.  The survival rate in the SLNB group was 
equivalent to that in the ALND group.  This suggests that SLNB with the dye only method 
can safely replace ALND as the procedure of choice for axillary staging in breast cancer 
patients with a clinically negative axilla.
Key words: breast cancer; sentinel lymph node biopsy
Axillary lymph node status is one of the most 
important prognostic indicators for relapse and 
survival in patients with breast cancer (Fisher et 
al., 1970).  Until the introduction of sentinel lymph 
node (SLN) mapping in the early 1990s, axil-
lary lymph node dissection (ALND) had been the 
standard surgical treatment for the axilla of breast 
cancer patients.  However, ALND is associated 
with major problems, including acute and chronic 
complications (Petrek et al., 2000). 
 The widespread use of screening mammog-
raphy often enables detection of breast cancer at 
an early stage and thus, the percentage of node-
positive patients who benefit from routine ALND is 
decreasing (Bass et al., 1999).  Consequently, SLN 
biopsy (SLNB) has now become the new standard 
of care for axillary staging in early breast cancer, 
and it has the potential to reduce the morbidity 
of the surgical procedure (Veronesi et al., 2003; 
Fleissig et al., 2006; Lucci et al., 2007).  The SLN 
identification rate has been reported to be 96% 
and SLNB sensitivity to be 93% in average (Kim 
et al., 2006).  Many published trials have reported 
false-negative rates of 5 to 10%, results which were 
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deemed acceptable for avoiding ALND in patients 
with a negative sentinel node (Liberman, 2000; 
Veronesi et al., 2003; Krag et al., 2007).
 While these initial studies are promising, 
follow-up data have been limited, especially for 
SLNB using the indocyanine green dye method 
(dye only method).  The aim of this study was to 
demonstrate the accuracy of SLNB using the dye 
only method without ALND, as an effective tool 
for axillary staging.  The survival of breast cancer 
patients negative to SLNB without ALND was 
compared to that of axillary lymph node-negative 
patients after ALND.
 
Subjects and Methods
 
Patients
 
A total of 174 patients with initial primary invasive 
breast carcinomas were treated in our Clinical De-
partment of University Hospital between January 
2000 and December 2008.  We divided them into 
2 groups of 108 SLNB-negative patients without 
ALND who were treated between May 2005 and 
December 2008 (SLNB group) and 66 axillary 
node-negative patients with ALND who were treat-
ed between January 2000 and April 2005 (ALND 
group).  All patients had clinically negative axil-
las.  Patients with in situ carcinomas, multicentric 
carcinomas, bilateral breast carcinomas, locally 
advanced disease with primary tumors greater than 
4 cm, clinically or pathologically positive axillary 
lymph nodes, or who underwent systemic primary 
therapy, were excluded from the study.  Informed 
consent was obtained from every patient.  All pa-
tients were treated with breast-conserving surgery 
or mastectomy.  Most patients with breast-con-
serving surgery received radiotherapy to the whole 
breast after surgery.  Most patients also underwent 
some type of systemic adjuvant therapy. 
  
SLNB and pathological analysis
 
SLNB was performed using the dye only method 
with 25 mg indocyanine green (Diagnogreen; 
Daiichi Pharmaceutical, Tokyo, Japan), which 
was diluted in 5 mL sterile, distilled water.  After 
induction of general anesthesia, 3- to 5-mL indo-
cyanine green was injected intradermally into the 
periareolar area.  A 3- to 4-cm axillary skin inci-
sion was made 5 or 10 min after the injection, in 
order to detect green-stained SLNs.  Intraoperative 
frozen-section analyses of the resected SLNs were 
performed.  All SLNs were bisected along the ma-
jor axis, and postoperatively, specimens were fixed, 
embedded in paraffin, and stained using standard 
histopathological procedures.  Patients with SLNs 
that were negative for malignancy by intraoperative 
analysis did not undergo additional ALND.
 
 
 
Statistical analysis
 
The disease free survival period was defined as 
the period from the date of operation to the date 
of the first confirmation of recurrence (i.e., lo-
cal recurrence or metastasis) or death from any 
cause, whichever came first.  The overall survival 
period was defined as that from the date of op-
eration to the date of death from any cause.  The 
Mann-Whitney U test or unpaired t-test was used 
for comparisons of continuous outcomes, while 
the 2 test was used for comparisons of categorical 
variables.  The disease free and overall survival 
curves were analyzed by the log-rank test.  A Cox 
proportional-hazards model was used to compare 
the SLNB and ALND groups, and to adjust for 
variables.  Significance was defined as P < 0.05.
  
Results
 
SLNB 
  
SLNs were identified in 130 of the 135 patients (SLN 
identification rate, 96.3%).  SLNs stained in frozen 
sections were negative in 108 of the 130 patients 
(83.1%).  Three of the 108 patients (2.8%) were 
positive to SLNB of permanent sections stained in 
hematoxylin and eosin (Fig. 1).  The mean number 
of SLNs per patient was 1.27 (range, 1–3).  Thus, 
we determined 108 patients to be SLNB-negative 
in frozen sections, and treated them as the SLNB 
group (Fig. 1).
 
 
130 patients (96.3%) 
   SLNs, detected 
108 patients (83.1%) 
    negative SLNB 
    in frozen section
  22 patients (16.9%) 
    positive SLNB 
    in frozen section
  3 patients (  2.8%) 
     positive SLNB 
     in permanent section
To analyze the survival rate in this study
To observe
  5 patients (100%)    negative ALND 
10 patients (45.5%)   negative ALND 
  0 patients (    0%)    positive ALND 
12 patients (54.5%)   positive ALND 
135 patients 
   early-stage, node 
   negative disease
    5 patients (   3.7%)   failed to detect SLNs 
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Follow-up data of SLNB
 Table 1.  Patient and tumor characteristics
 SLNB group ALND group P value
 [108] [66]
Age  Median (min–max) (year) 60 (27–86) 54 (30–87) 0.2163
Histology Invasive ductal carcinoma 94 58 1.0000
 Others 14  8
Tumor size Mean (min–max) (cm)  1.6 (0.5–3)  1.9 (0.5–3.5) 0.0022*
Tumor laterality Right 49 35 0.2625
 Left 59 31
Estrogen receptor status Positive 88 45 0.0509
 Negative 20 21
Progesteron receptor status Positive 66 38 0.7734
 Negative 42 28
HER-2 status Positive  9  6 0.3757
 Negative 94 37
 Missing  5 23
Menopausal status Before 27 25 0.0673
 After 81 41
Tumor treatment Breast conserving surgery
 84 53 0.8624
    ± radiation therapy
 Mastectomy 24 13
Systemic therapy None 12  7 0.2185
 Endocrine therapy 82 43
 Chemotherapy  9 11
 Endocrine therapy + chemotherapy  5  5
 ALND, axillary lymph node dissection; SLNB, sentinel lymph node biopsy.  
 [   ], number of patients.   
* P < 0.05 with unpaired t-test.
Fig. 1.  Qualification of patients of the SLNB group.  We analyzed the survival of 108 patients observed to be negative to 
SLNB intraoperatively in frozen section and successively in permanent section.  ALND, axillary lymph node dissection; 
SLNB, sentinel lymph node biopsy.
 
Survival data
 
Patient and tumor characteristics of the SLNB and 
ALND groups are listed in Table 1.  With the ex-
ception of tumor size (unpaired t-test) and follow-
up period, differences were not significant in age, 
tumor histology, tumor laterality, estrogen receptor 
status, progesterone receptor status, HER-2 status, 
menopausal status, tumor treatment and systemic 
therapy. 
 In the SLNB group, the median follow-up 
period was 25 months (range, 0–55 months).  There 
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were no axillary recurrences in the 108 patients 
who underwent SLNB without ALND.  A metas-
tasis to the bone was observed in 1 patient.  Three 
patients died of other causes.  The disease free and 
overall survival rates at 4.5 years were 90.9% and 
91.9%, respectively (Figs. 2 and 3). 
Fig. 2.  Changes in disease free survival rate in the SLNB 
and ALND groups.  The difference in prognostic signifi-
cance of the disease free survival rate between groups 
was P = 0.9252.  ALND, axillary lymph node dissection; 
SLNB, senile lymph node biopsy.  [  ], number of patients. 
Fig. 3.  Changes in overall survival rate in the SLNB and 
ALND groups.  The difference in prognostic significance 
of the overall survival rate between groups was P = 0.1862. 
ALND, axillary lymph node dissection; SLNB, senile 
lymph node biopsy.  [  ], number of patients.
 In the ALND group, the median follow-up pe-
riod was 75 months (range, 0–116 months).  There 
were no axillary recurrences in the 66 patients who 
underwent ALND.  Contralateral breast cancer was 
observed in 3 patients, ipsilateral recurrence in 1 
patient and cervical lymph node metastasis in 1 
patient.  Three patients died of other causes.  The 
disease free and overall survival rates at 4.5 years 
were 91.7% and 98.3%, respectively (Figs. 2 and 3). 
After adjusting for tumor size in Cox proportional-
hazards model analysis, tumor size was not a sig-
nificant predictor for both survival rates.
  
 
Discussion
 
In this study, we determined the disease free and 
overall survival rates in patients undergoing SLNB 
without ALND, and compared with those in node-
negative patients undergoing ALND.  Although 
several studies have validated the accuracy of 
SLNB for axillary staging (Krag et al., 1998; Lo 
et al., 2006; Gill, 2009), the data on the long-term 
outcome of SLNB without ALND have been lim-
ited. 
 The 4.5-year overall and disease free survival 
rates we observed in the SLNB group were 90.9% 
and 91.9%, respectively.  Other studies have re-
ported that for early-stage breast cancer, the 5-year 
overall survival rate was 89 to 96.7% in the SLNB 
group, and 85 to 88.5% in the ALND group (Kuijt 
et al., 2003; Langer et al., 2009), and that the 5-year 
disease free survival rate was 87.6 to 96.0% in 
the SLNB group and 87.2 to 89.9% in the ALND 
group (Zavagno et al., 2008; Langer et al., 2009). 
These suggest that SLNB without ALND provides 
at least equivalent or improved disease free and 
overall survival rates compared with ALND for 
node-negative patients.  This is most likely because 
of more accurate staging resulting from the focused 
pathologic examination on 1 or just a few nodes. 
Prospective randomized comparisons of SLNB 
with routine ALND are now ongoing in the Ameri-
can National Surgical Adjuvant Breast and Bowel 
Project Protocol-B 32 and the European ALMA-
NAC trials. 
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Follow-up data of SLNB
 In our study with a median follow-up period 
of 25 months, there were no axillary recurrences in 
the SLNB group.  All of our patients were negative 
to SLNB with the dye only method, which was suc-
cessively defined in hematoxylin and eosin staining 
only of the largest single section of the SLN, and so 
isolated tumor cells or a micrometastasis may have 
been overlooked.  We calculated the mean rate of 
axillary recurrence in SLNB-negative patients to 
be 0.51% from results of 8 different studies with 
a mean follow-up period of 34.9 months (Salem, 
2009).  Thus far in the current literature, research 
has not provided evidence that SLN micrometasta-
sis leads to axillary recurrence or distant disease, 
which supports the theory that formal ALND may 
be omitted in these patients (Langer et al., 2005). 
In patients with isolated tumor cells or microme-
tastasis who received adjuvant therapy, disease-
free survival was improved (de Boer et al., 2009). 
These results suggest that adjuvant treatment con-
tributes to the low axillary failure rate, and that 
good disease free survival may have resulted in 
good overall survival in our SLNB group, because 
90% of the patients in our study received systemic 
adjuvant therapy.  Another reason for our results 
may be the short follow-up period, but a median 
time interval of 19 months for local recurrence 
after ALND has been reported in another study 
(Newman et al., 2000). 
 We used indocyanine green dye at SLNB.  In-
docyanine green dye has been commonly used in 
clinical practice and the safety has been established 
when SLNB was introduced.  Furthermore, the side 
effect associated with allergy has been concerned 
about other dyes.  Nationwide questionnaire survey 
on SLNB reported no side effects for indocyanine 
green dye (Tsugawa et al., 2009).
 The main limitation of the present study is 
that patient groups studied in 2 different periods 
of time were compared.  However, follow-up pro-
cedures and adjuvant treatments were similar for 
both groups, because all patients had early-stage, 
node-negative disease.  Second, although most 
patient and tumor characteristics were similar in 
both groups, there were significantly more patients 
with larger tumor size in the ALND group than in 
the SLNB group.  However, tumor size was not a 
significant predictor for the disease free and overall 
survival rates after adjusting for the factor in Cox 
proportional-hazards model analysis.
 In conclusion, survival in node-negative breast 
cancer patients undergoing SLNB with the dye 
only method without ALND was equivalent to that 
in node-negative breast cancer patients undergo-
ing ALND.  This suggests that SLNB with the 
dye only method can safely replace ALND as the 
procedure of choice for axillary staging in breast 
cancer patients with a clinically negative axilla. 
 
 
References
 1 Bass SS, Lyman GH, McCann CR, Ku NN, Berman 
C, Durand K, et al.  Lymphatic mapping and sentinel 
lymph node biopsy.  Breast J 1999;5:288–295
 2 de Boer M, van Deurzen CH, van Dijck JA, Borm GF, 
van Diest PJ, Adang EM, et al.  Micrometastases or iso-
lated tumor cells and the outcome of breast cancer.  N 
Engl J Med 2009;361:653–663.
 3 Fisher B, Slack NH.  Number of lymph nodes examined 
and the prognosis of breast carcinoma.  Surg Gynecol 
Obstet 1970;131:79–88.
 4 Fleissig A, Fallowfield LJ, Langridge CI, Johnson L, 
Newcombe RG, Dixon JM, et al.  Post-operative arm 
morbidity and quality of life Results of the ALMANAC 
randomised trial comparing sentinel node biopsy with 
standard axillary treatment in the management of pa-
tients with early breast cancer.  Breast Cancer Res Treat 
2006;95:279–293. 
 5 Gill G.  Sentinel-lymph-node-based management or 
routine axillary clearance? One-year outcomes of sen-
tinel node biopsy versus axillary clearance (SNAC):  a 
randomized controlled surgical trial.  Ann Surg Oncol 
2009;16:266–275.
 6 Kim T, Giuliano AE, Lyman GH.  Lymphatic mapping 
and sentinel lymph node biopsy in early-stage breast 
carcinoma: a metaanalysis.  Cancer 2006;106:4–16.
 7 Krag D, Weaver D, Ashikaga T, Moffat F, Klimberg 
VS, Shriver C, et al.  The sentinel node in breast can-
cer – a multicenter validation study.  N Engl J Med 
1998;339:941–946.
 8 Krag DN, Anderson SJ, Julian TB, Brown AM, Harlow 
SP, Ashikaga T, et al.  Technical outcomes of sentinel-
lymph-node resection and conventional axillary-lymph-
node dissection in patients with clinically node-negative 
breast cancer: results from the NSABP B-32 randomised 
phase III trial.  Lancet Oncol 2007;8:881–888.  
52
Y. Uchida et al.
 9 Kuijt GP, van de Poll-Franse LV, Voogd AC, Nieuwen-
huijzen GA, Roumen RM.  Survival after negative sen-
tinel lymph node biopsy in breast cancer at least equiva-
lent to after negative extensive axillary dissection.  Eur J 
Surg Oncol 2003;29:216–220.
10 Langer I, Marti WR, Guller U, Moch H, Harder F, 
Oertli D, et al.  Axillary recurrence rate in breast cancer 
patients with negative sentinel lymph node (SLN) or 
SLN micrometastases: prospective analysis of 150 pa-
tients after SLN biopsy.  Ann Surg 2005;241:152–158.
11 Langer I, Guller U, Hsu-Schmitz SF, Ladewig A, Viehl 
CT, Moch H, et al.  Sentinel lymph node biopsy is asso-
ciated with improved survival compared to level I & II 
axillary lymph node dissection in node negative breast 
cancer patients.  Eur J Surg Oncol 2009;35:805–813. 
12 Liberman L.  Pathologic analysis of sentinel lymph 
nodes in breast carcinoma.  Cancer 2000;88:971–977. 
13 Lo YF, Hsueh S, Ma SY, Chen SC, Chen MF.  Radiogu-
ided sentinel lymph node biopsy in early breast cancer: 
experience at Chang Gung Memorial Hospital.  Chang 
Gung Med J 2006;29:458–467.
14 Lucci A, McCall LM, Beitsch PD, Whitworth PW, 
Reintgen DS, Blumencranz PW, et al.  Surgical com-
plications associated with sentinel lymph node dis-
section (SLND) plus axillary lymph node dissection 
compared with SLND alone in the American College of 
Surgeons Oncology Group Trial Z0011.  J Clin Oncol 
2007;25:3657–3663.
15 Newman LA, Hunt KK, Buchholz T, Kuerer HM, Vlas-
tos G, Mirza N, et al.  Presentation, management and 
outcome of axillary recurrence from breast cancer.  Am 
J Surg 2000;180:252–256.
16 Petrek JA, Pressman PI, Smith RA.  Lymphedema:  cur-
rent issues in research and management.  CA Cancer J 
Clin 2000;50:292–307.
17 Salem A.  Sentinel lymph node biopsy in breast can-
cer: a comprehensive literature review.  J Surg Educ 
2009;66:267–275.
18 Tsugawa K, Nakamura S.  The results of a questionnaire 
survey on sentinel lymph node biopsy for breast cancer 
patients in Japan.  Nyugan No Rinsho 2009;24:265–270 
(in Japanese with English abstract). 
19 Veronesi U, Paganelli G, Viale G, Luini A, Zurrida 
S, Galimberti V, et al.  A randomized comparison of 
sentinel-node biopsy with routine axillary dissection in 
breast cancer.  N Engl J Med 2003;349:546–553.
20 Zavagno G, De Salvo GL, Scalco G, Bozza F, Barutta 
L, Del Bianco P, et al.  A Randomized clinical trial on 
sentinel lymph node biopsy versus axillary lymph node 
dissection in breast cancer:  results of the Sentinella/
GIVOM trial.  Ann Surg 2008;247:207–213.   
Received April 2, 2010; accepted April 23, 2010
Corresponding author:  Naotaka Uchida, MD, PhD
